Nurse practitioners provide insight on issues surrounding the administration of dual HER2-targeted therapy in the neoadjuvant/adjuvant setting and counseling patients on common AEs associated with trastuzumab-pertuzumab for the treatment of HER2+ breast cancer.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Abemaciclib Indication Expands to Include HR+, HER2–, Node+, High-Risk, Early Breast Cancer
March 3rd 2023Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.
Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer
GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
2 Clarke Drive
Cranbury, NJ 08512